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Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder associated with a premutation
repeat expansion (55–200 CGG repeats) in the 5′ noncoding region of the FMR1 gene. Solitary intranuclear
inclusions within FXTAS neurons and astrocytes constitute a hallmark of the disorder, yet our understanding of how
and why these bodies form is limited. Here, we have discovered that FXTAS inclusions emit a distinct
autofluorescence spectrum, which forms the basis of a novel, unbiased method for isolating FXTAS inclusions by
preparative fluorescence-activated cell sorting (FACS). Using a combination of autofluorescence-based FACS and
liquid chromatography/tandem mass spectrometry (LC-MS/MS)-based proteomics, we have identified more than
two hundred proteins that are enriched within the inclusions relative to FXTAS whole nuclei. Whereas no single
protein species dominates inclusion composition, highly enriched levels of conjugated small ubiquitin-related
modifier 2 (SUMO 2) protein and p62/sequestosome-1 (p62/SQSTM1) protein were found within the inclusions.
Many additional proteins involved with RNA binding, protein turnover, and DNA damage repair were enriched
within inclusions relative to total nuclear protein. The current analysis has also allowed the first direct detection,
through peptide sequencing, of endogenous FMRpolyG peptide, the product of repeat-associated non-ATG (RAN)
translation of the FMR1 mRNA. However, this peptide was found only at extremely low levels and not within whole
FXTAS nuclear preparations, raising the question whether endogenous RAN products exist at quantities sufficient to
contribute to FXTAS pathogenesis. The abundance of the inclusion-associated ubiquitin- and SUMO-based
modifiers supports a model for inclusion formation as the result of increased protein loads and elevated oxidative
stress leading to maladaptive autophagy. These results highlight the need to further investigate FXTAS
pathogenesis in the context of endogenous systems.
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Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is
a progressive X-linked neurodegenerative disorder that
arises from premutation CGG-repeat expansions (55-
200 repeats) in the 5′ noncoding portion of the FMR1
gene [42]. The disorder, which generally has a clinical
onset after age fifty, has core features of progressive
cerebellar gait ataxia and kinetic tremor, with associated
features of executive dysfunction, cognitive decline,
neuropathy, dysautonomia, and Parkinsonism [14, 42,
45, 46]. Neuropathologic features of FXTAS include
prominent white matter disease, loss of brain volume,
Purkinje cell dropout, and solitary ubiquitin-positive in-
clusions within the nuclei of neurons and astrocytes [42,
44]. Inclusion formation is favored in cortical and hippo-
campal neurons and astrocytes and can be found in 2–
20% of these cells in many patients [38]. Although many
neurodegenerative diseases form inclusions and other
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aggregates in brain tissue, almost all of them include
cytoplasmic aggregate formation and form multiple in-
clusions per cell [3, 7, 11, 17, 59]. Although FXTAS in-
clusions are found almost exclusively as solitary, spherical
particles – distinct from nucleoli – within each nucleus,
twinning of inclusions has been reported [5, 38, 39]. The
mechanism(s) governing inclusion formation, and the na-
ture of their composition, remain largely unknown; a better
understanding of the properties of inclusions is likely to be
key in understanding FXTAS pathogenesis.
FXTAS is largely limited to the premutation range, where
there is normal to increased transcription of the expanded
CGG-repeat mRNA [42, 68, 134]. The absence of the neu-
rodegenerative phenotype for alleles in the full mutation
range (>200 CGG repeats), with rare exceptions among
mosaics [55, 82, 114], is thought to be due to methylation-
coupled transcriptional silencing of the FMR1 gene. The re-
quirement for transcriptional activity supports an RNA
gain-of-function toxicity model [43, 78], as described earlier
for myotonic dystrophy (DM) [25, 30, 89, 136].
Several specific models have been proposed to explain
how neurotoxicity arises from the expanded CGG-repeat
mRNA [118]. Analogous to the model for DM [136], the
FXTAS mRNA sequestration model posits that the ex-
panded-repeat FMR1 mRNA binds excessive amounts of
one or more RNA-binding proteins [60, 115, 126, 127,
130], thus rendering those proteins functionally de-
pleted. A second model proposes that initiation of trans-
lation at a non-AUG codon upstream of the CGG repeat
generates an out-of-frame, toxic FMRpolyG protein [35,
125, 137]. Several sub-mechanisms are related to the
FMRpolyG mechanism, including its inhibition of the
ubiquitin-proteasomal system [53, 104] and co-aggrega-
tion with the nuclear lamina-associated polypeptide 2
beta (LAP2β) [125] or the splicing regulator trans-
former-2 protein homolog alpha (TRA2A) [19]. Previous
studies have also found evidence for mediators of a
DNA damage response (DDR) in both mouse and hu-
man tissues [44, 54, 58, 117]. However, the data of Robin
et al. [117] suggest that the DDR may be a late response
to early-onset calcium dysregulation and oxidative stress
in affected neurons, progressing through the course of
FXTAS pathogenesis. In support of this hypothesis, the
FMR1 premutation model exhibits functional abnormal-
ities early in development [16, 18, 23, 64, 81]. In all of
these models, the role of inclusion formation/compos-
ition is of central importance, particularly with respect
to its role as a repository for the products of aggrega-
tion/co-aggregation and to its use as a target for anti-
body staining to identify the proteins involved with
FXTAS pathogenesis. Accordingly, determining both the
general composition of the FXTAS inclusions and the
estimated relative abundances of the component pro-
teins is of critical importance.
Due to the technical challenges associated with purify-
ing the FXTAS inclusions, their composition has been
difficult to ascertain. Furthermore, the reliance on im-
munofluorescence methods to probe inclusion compos-
ition, and to direct their isolation, as in Iwahashi et al.
[58], can introduce substantial bias because of the poten-
tial for antibody cross-reactivity and variability of the ac-
cessibility of their protein targets. In our efforts to
address this issue, we have now observed that the FXTAS
inclusions emit considerable autofluorescence across a
broad range of wavelengths. By coupling FXTAS inclusion
autofluorescence with fluorescence-activated cell sorting
(FACS), we have been able to exploit this intrinsic prop-
erty for rapid isolation of the inclusions for downstream
characterization. We have coupled this unbiased autofluo-
rescence-based isolation method with mass spectrometry
(MS)-based proteomics to characterize the protein com-
position of FXTAS inclusions. Although using autofluo-
rescence for sorting intracellular aggregates is new in the
field of neurodegenerative disease, similar strategies have
already been successfully applied in other fields [119, 129,
147]. This analysis allows us to estimate the relative abun-
dances of certain proteins within FXTAS inclusions with-
out the potential confounders of autofluorescence or
antibody cross-reactivity, thus aiding the evaluation of
existing models for FXTAS pathogenesis.
In the current work, we show that FXTAS inclusions
are composed principally of protein and that, of the
nearly 200 proteins that are enriched in the inclusions,
over half are involved in RNA binding and/or protein
turnover. In particular, heterogeneous nuclear ribonu-
cleoproteins (hnRNPs), molecular chaperones, and pro-
tein modifiers are prevalent. No single protein species
dominates the collection of enriched proteins. FMRpo-
lyG is not detected in the FXTAS nuclei and is only de-
tected at <0.05% molar abundance in the inclusions
themselves. Among the most highly abundant of the
enriched proteins are the small ubiquitin-related modi-
fier 2 (SUMO 2), ubiquitin, and p62/sequestosome-1
(p62/SQSTM1; hereafter designated p62). Western blot
and immunofluorescence experiments confirm that con-
jugated SUMO 2 is present at over 10 times higher levels
in FXTAS patient brain nuclei compared with control
brain nuclei and exists primarily in nuclear aggregates.
SUMO 2 immunoprecipitation (IP) proteomics demon-
strate that conjugated SUMO 2 in FXTAS samples is
not due to conjugation to any one specific protein, but
an overall higher level of conjugation to numerous pro-
teins, specifically to DDR mediators and proteins in-
volved in cellular response to oxidative stress. These
results indicate that inclusions are mainly accumulations of
proteins destined for removal that may have aggregated in
response to the presence of RNA and/or exceeded the cap-
acity of the nuclear proteasomal machinery. We suggest
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that once the size/abundance of the aggregates exceeds the
threshold of proteasomal degradation, the continued aggre-
gation leads to inclusion formation. For non-dividing cells,
p62-directed autophagy is not available to clear the large
nuclear aggregates, culminating in the trapped inclusion
mass that is a hallmark feature of FXTAS.
Materials and Methods
Patient sample information and tissue preparation
Human postmortem frontal cortex samples from six
FXTAS, one fragile X syndrome (FXS), one amyotrophic
lateral sclerosis (ALS), one Parkinson’s disease (PD), and
three control brains were obtained from the FXTAS brain
repository at the University of California, Davis (UCD),
School of Medicine. Additional human postmortem frontal
cortex samples from two Alzheimer’s disease (AD), one
frontotemporal dementia (FTD), two Huntington’s Disease
(HD), and two progressive supranuclear palsy (PSP) cases
were obtained from the NIH Brain & Tissue Repository.
Human postmortem frontal cortex samples were also ob-
tained from two AD cases through the UCD Alzheimer’s
Disease Center. Tissue specimens were obtained through
consented autopsies with their respective institutional re-
view board approvals (UCD and VA West Los Angeles
Medical Center). FXTAS patients had all been established
through clinical diagnosis based on the presence of
intention tremor, cerebellar ataxia, and parkinsonism, and
were confirmed to have FXTAS based on the postmortem
identification of intranuclear ubiquitin-positive inclusions
in brain cells. Control tissue was obtained postmortem
from individuals who did not have any significant neuro-
logical history, including encephalitis, epilepsy, demyelinat-
ing disease, dementia, or concurrent neurodegenerative
disease. AD was rated using Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) criteria and
Braak stage. All other brain tissues were neuropathologi-
cally examined and diagnosed according to clinical symp-
toms, gross features, and microscopic features. Samples
were collected at the time of death and stored at -80 °C
until used. Frozen tissue was dissected from the frontal cor-
tex. High-premutation (hpCGG) and wild type (WT) mice
with the C57BL/6 background were housed under standard
vivarium conditions. All animal use protocols were ap-
proved by the Institutional Animal Care and Use Commit-
tee at UCD. Cerebral cortex was dissected and flash frozen
in liquid nitrogen immediately after mice were sacrificed,
then stored at -80 °C until used. Fibroblasts and lympho-
cytes used were collected and cultured as previously de-
scribed in Pretto et al. [113]. All sample information is
provided in Additional file 1: Tables S1-S3.
Immunofluorescence
Slides of brain nuclei were prepared using methods de-
scribed previously [57, 58]. Slides were permeabilized in
PBS + 0.5% Triton X-100 for 15 min at room temperature,
then blocked in blocking buffer [3% bovine serum albumin
(BSA) 0.5% Tween-20, in 1x PBS] for 30 min at room
temperature. Primary antibody was diluted to desired con-
centration in detection buffer (1% BSA, 0.5% Tween-20, in
1x PBS), and slides were incubated in primary antibody for
either 1 hr at room temperature or overnight at 4 °C in a
humid chamber. After washing in PBS + 0.1% Tween-20,
the slides were incubated in secondary antibody for 1 hr at
room temperature in a humid chamber and stained with
DAPI before coverslips were mounted with either SlowFade
Antifade Mountant (for immediate viewing) or Prolong
Diamond Antifade Mountant (for longer term viewing or
storage). For each immunofluorescence experiment, sec-
ondary antibody-only slides and DAPI-only slides were pre-
pared for comparison. Immunofluorescence primary
antibodies: rabbit anti-SUMO 2/3 (Abcam ab3742; diluted
1:200), mouse anti-SUMO 2/3 (Abcam ab81371; diluted 1:
500), rabbit anti-p62/SQSTM1 (Invitrogen 701510; diluted
1:100), mouse anti-ubiquitin (Bio-rad MCA-1398G; diluted
1:200), rabbit anti-ubiquitin (Abcam 134953; diluted 1:100).
Secondary antibodies: goat anti-rabbit Alexa-647 (Abcam
ab150083; diluted 1:500), goat anti-mouse Alexa-647
(Abcam ab150115; diluted 1:500), goat anti-mouse Alexa-
488 (Abcam ab150113; diluted 1:500), goat anti-rabbit
Alexa-488 (Abcam ab150077; diluted 1:500), goat anti-
rabbit Alexa-532 (Invitrogen A-11009; diluted 1:500).
DNA fluorescence in situ hybridization (FISH)
To generate DNA FISH probes, biotin-labeled PCR
amplicons corresponding to unique regions spanning
and surrounding the FMR1 gene were generated.
Metaphase slides were prepared from primary patient
fibroblasts by applying colcemid to fibroblasts at
~70% confluency for 3 hr before cells were collected
by trypsinization. Cells were incubated in KCl buffer
before fixation using 3:1 methanol acetic acid. 0.3-0.5
μg of probe per slide was applied overnight to cells
that were permeabilized successively in several buffers
containing detergents, formamide, and ethanol. Bound
biotin probe was incubated with Streptavidin bound
to Alexa-555 (Invitrogen S32355) at a 1:200 dilution
before staining with DAPI and mounting with Pro-
long Diamond Antifade Mountant.
Inclusion fractionation
Continuous sucrose gradients were prepared and frozen
beforehand using sucrose solutions at concentrations of
2.6, 2.5, 2.4, 2.3, and 2.2 M. In thin-walled polyallomer
centrifuge tubes, 6 ml of each solution was added and
subsequently submerged in a dry ice ethanol bath, start-
ing with the most concentrated at the bottom and pro-
gressing upwards to the least concentrated at the top.
Frozen gradients were stored at -20 °C.
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Nuclear isolation was performed on frozen human
cortical tissue using modified methods from Iwahashi et
al. [57] and McEwen and Zigmond [94]. Nuclei were
centrifuged and resuspended in 800 μl of BDC + NP-40
[40 mM Tris, 10 mM NaCl, 10 mM CaCl2, 5 mM
MgCl2, 0.1% NP-40, Complete protease inhibitor
(Roche), RNase inhibitor (NEB), pH 7.9] and 200 U/ml
of DNase I (NEB). Nuclei were Dounce-homogenized
with a tight pestle on ice for 30 strokes, after which, the
sample was rotated at 37 °C for 6 hr with periodic mix-
ing by pipetting to reduce viscoelasticity. An aliquot was
removed at this point to serve as total nuclear protein
samples for MS. The remaining sample was centrifuged
at 16,000 RCF for 10 min at 4 °C, and the pellet contain-
ing FXTAS inclusions was resuspended in BCC (20 mM
HEPES, 400 mM NaCl, 1 mM DTT, 1 mM EDTA, 1
mM EGTA, Complete protease inhibitor, pH 7.4) with
RNase inhibitor and frozen at -80 °C overnight.
Pre-made sucrose gradients were taken from -20 °C and
placed at 4 °C overnight to allow thawing. The frozen, re-
suspended inclusion samples were thawed on ice, centri-
fuged at 16,000 RCF for 10 min at 4 °C, then diluted to 10
ml of BCC and carefully pipetted onto the top surface of
the sucrose gradient, followed by ultracentrifugation at
100,000 RCF for 6 hr at 4 °C. 2 ml fractions were collected
through a small needle puncture at the bottom of each
centrifuge tube. Each fraction was diluted with BCC, cen-
trifuged at 3,000 RCF for 10 min at 4 °C, then resuspended
in BCC + RNase inhibitor and stored at -80 °C until FACS
processing. Slides were made of each fraction to confirm
presence of inclusions at fractions corresponding to dens-
ities of approximately 1.30 g/ml.
Western blot
Concentrations of protein lysates were measured using
the Pierce BCA or MicroBCA assay kit (Thermo Scien-
tific), and either 10 μg or 20 μg of protein per sample
was mixed with 1x Tris buffered saline (TBS) and
Laemmli buffer (375 mM Tris-HCl, 6% SDS, 4.8% gly-
cerol, 9% 2-Mercaptoethanol, 0.01% bromophenol blue)
to obtain a total volume of 30 μl. Samples were held at
95 °C for 5–10 min and allowed to cool to room
temperature before loading onto Criterion TGX 18-well
Any kD polyacrylamide gels (Bio-rad) alongside the
Chameleon Duo protein ladder (Li-Cor). Samples were
run at 20 mA for 20 min until clearly stacked in the gel,
then run at 80 mA for 45 min. Gel was then transferred
overnight at 4 °C onto a nitrocellulose membrane. The
membranes were stained for total protein using Revert
Total Protein Stain (Li-Cor) and imaged immediately for
total protein on a Li-Cor Odyssey Imager before incu-
bating in blocking buffer (5% BSA in 1x TBS) at room
temperature for 1 hr. Primary antibodies were diluted in
detection buffer (5% BSA + 0.1% Tween-20 in 1x TBS)
and membranes were incubated in primary antibody
overnight at 4 °C. The membrane was washed three
times in wash buffer (0.1% Tween-20 in 1x TBS) before
incubating in secondary antibody diluted in detection
buffer at room temperature for 1 hr. Membranes were
again washed three times in wash buffer and once in 1x
TBS before imaging on a Li-Cor Odyssey Imager. Image
processing and densitometry was performed using Ima-
geStudio software. Specific protein signal was normal-
ized both to adjacent background on the image and to
total protein signal for each lane. Western blot primary
antibodies: rabbit anti-SUMO 2/3 (Abcam ab3742; di-
luted 1:1,000), rabbit anti-p62/SQSTM1 (Invitrogen
701510; diluted 1:500). Secondary antibody: IRDye
800CW donkey anti-rabbit (Li-Cor; diluted 1:20,000).
Fluorescence-activated cell sorting (FACS) purification of
inclusions
To sort inclusions for MS, two FXTAS patients (cases B3
and B6 from Table S1) were chosen for analysis alongside
one control sample (case B8 from Table S1). Frozen inclu-
sion-enriched fractions of sucrose density gradients from
FXTAS nuclei, and equivalent density fractions from un-
affected individuals, were thawed and immediately assessed
for particle scatter and intrinsic autofluorescence character-
istics by flow cytometry using a Beckman Coulter MoFlo
Astrios EQ cell-sorting flow cytometer. As observed by
fluorescence microscopy (Fig. 1 a), the inclusions present in
FXTAS tissue homogenates were small, relatively
homogenous in size, and primarily exhibited green autoflu-
orescence (500–565 nm) following 488 nm laser excitation.
These green fluorescent particles were not apparent in
similarly prepared samples from control tissues. As is
standard practice for detection of small subcellular particles
[109], we used logarithmic scaling to distinguish inclusions
from debris artifacts introduced in the sample buffer. We
then removed larger aggregates by plotting the duration of
90° laser light scatter to remove objects with markedly in-
creased laser dwell rates relative to the shorter transit times
of single particles. Using these settings, we compared the
strength of the autofluorescence signals in FXTAS and con-
trol samples across several detectors. We noted that the
strongest fluorescence signal was measured in the green de-
tector from 488 nm laser excitation, but this signal was
markedly diminished for ≥670 nm wavelengths when sub-
jected to 488, 561, or 640 nm laser excitation. In total, 8.6
million inclusions were sorted from one FXTAS patient
sample and 6.5 million inclusions were sorted from a sec-
ond FXTAS patient sample. Sorted inclusions were centri-
fuged at 3,000 RCF for 1 hr at 4 °C, and the pellets were
pooled for each patient and resuspended in PBS. Aliquots
of all samples were taken for the MicroBCA assay. SDS was
added to samples to a final concentration of 5% to dissolve
insoluble material. Sorted inclusion samples did not contain
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any visible precipitate after samples were mixed in SDS.
MicroBCA assay kits were used according to the manufac-
turer’s instructions. Sorted inclusion samples yielded com-
parable total protein concentrations, at 50 μg/ml for the
sample containing 6.5 million inclusions, and 68 μg/ml for
the sample containing 8.6 million inclusions. Based on
these concentrations, inclusions contain approximately
4x10-6 μg of protein per inclusion. BCA estimates were
used to obtain 25 μg of protein from each sample for MS
analysis.
SUMO 2/3 IP from nuclear lysate
A total of 6 g of frozen frontal cortical tissue, previously
powdered under liquid nitrogen, was processed from two
Fig. 1 (See legend on next page.)
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FXTAS patients and two age-matched control patients
(FXTAS samples B2 and B4 and control samples B7 and
B8 from Table S1). Nuclear isolation was performed as de-
scribed above, except 1 mM EDTA, 1 mM EGTA, and 50
mM N-ethylmaleimide (Millipore Sigma) was added to
the buffers. Isolated nuclei were lysed, passed through a
27-gauge needle, heated, then diluted before being centri-
fuged to remove any remaining insoluble material. Each
sample was incubated with SUMO 2/3 antibody for 1 hr
at 4 °C with rotation, and Protein G Magnetic Beads
(NEB) were incubated with lysate-antibody mixture for 3
hr at 4 °C with rotation. Beads were then placed on a mag-
netic rack and the supernatant was collected to be run on
western blot as the nonbound fraction. Approximately 1/
10 of the beads from each IP was separated and eluted
using urea elution buffer (7 M urea, 20 mM Tris, pH 7.5,
100 mM NaCl) to be run on western blots as IP elute. The
remaining beads were washed three times with 50 mM
triethylammonium bicarbonate (TEAB) buffer before on
bead digestion.
Proteomics sample preparation
For proteomic analysis of isolated inclusions and total
nuclear protein, sample eluates were dried down in a
Centrivap centrifugal vacuum concentrator (Labconco,
Kansas City, USA) and reconstituted in 50 μl of SDS
solubilization buffer (5% SDS, 50 mM TEAB, 1X Phos-
STOP phosphatase and Complete mini protease inhibi-
tor tabs). Samples were clarified by centrifugation at 20,
000 RCF for 10 min, supernatants set aside, and the
resulting pellet further solubilized with 45 μl 100% for-
mic acid for 1 hr at 37 °C. Solubilized pellets were dried
down and recombined with soluble supernatants for
analysis. Each volume of normalized sample was enzy-
matically digested with trypsin using S-Trap micro (Pro-
tifi, Huntington, NY) spin columns according to
manufacturer instructions with the following modifica-
tions: samples were reduced with 20 mM DTT (Milli-
pore Sigma) for 30 min at 56 °C, alkylated with 40 mM
IAA (Millipore Sigma) for 30 min at room temperature,
and trypsin (Worthington, Lakewood, NJ, USA) was
added at a 1:12.5 ratio (enzyme (μg): protein (μg)) and
reacted for 2 hr at 47 °C.
For FMRpolyG-GFP heterologous expression samples,
harvested cell pellets were lysed directly in 200 μl SDS
solubilization buffer with sonication (Qsonica Q125, New-
ton, CT; 2 rounds of alternating 10 sec on/10 sec off at
20% amplitude). For each sample, protein concentration
was determined by BCA assay, volume was normalized to
140 μg of total protein, reduced and alkylated, and enzy-
matically digested with trypsin using S-Trap mini (Protifi)
spin columns according to manufacturer instructions with
the following modifications: samples were reduced with
20 mM DTT for 10 min at 50 °C, alkylated with 40 mM
IAA for 30 min at room temperature, and two rounds of
trypsin were added at a 1:25 ratio (enzyme (μg): protein
(μg)) and reacted first for 2 hr at 37 °C followed by a sec-
ond round overnight at 37 °C.
Sumo-IP samples were on-bead digested with 36 μg
trypsin overnight at 37 °C in 50 mM TEAB without re-
duction or alkylation. Supernatants containing digested
peptides were acidified to 1% TFA final concentration.
All resulting sample elutes were dried and reconstituted
in 2% acetonitrile/0.1% TFA for LC-MS/MS analysis.
LC-MS/MS and Data Analysis
Digested peptides were analyzed by LC-MS/MS on a
Thermo Scientific Q Exactive Plus Orbitrap Mass Spec-
trometer (Waltham, MA, USA) in conjunction with an
EASY-nLC 1200 UHPLC and Proxeon nanospray source
operating in positive ionization mode. Peptides were
loaded on a 100 μm x 25 mm Magic C18 100Å 5U re-
verse phase trap before being separated using a 75 μm x
150 mm Magic C18 200Å 3U reverse phase column.
Peptides were eluted with an increasing percentage of
acetonitrile over the course of a 90- or 120-min gradient
with a flow rate of 300 nl/min. An MS survey scan was
obtained for the m/z range 350–1600 and acquired with
(See figure on previous page.)
Fig. 1 a,c Flow-sorted FXTAS inclusions exhibit the same size and autofluorescent properties as in situ FXTAS inclusions. FXTAS inclusions exhibit
strong autofluorescence at 480 nm and 545 nm, and weak autofluorescence at 360 nm and 620 nm wavelengths. Inclusions sorted by flow cytometry
were verified by microscopy to confirm that sorted inclusions exhibit no significant difference from FXTAS inclusions viewed in situ. Slides were stained
with DAPI only and viewed at 100x. Orange arrows denote inclusions, upper left labels indicate the wavelength used for the image, and upper right
labels indicate the exposure level used to take the image. No postprocessing adjustments were made to brightness/contrast. b Fractions enriched in
inclusions and submitted for FACS contain a population of FXTAS-specific particles identified by size and fluorescence properties. Logarithmic scaling
was used on the detectors assigned to laser light scatter measurements (Inclusion scatter), and larger aggregates were removed by plotting the
duration of 90° laser light scatter to remove objects with markedly increased laser dwell rates relative to the shorter transit times of single particles
(Single inclusions). Sorted particles were identified as a population in FXTAS samples that was absent in control samples which exhibited strong green
fluorescence emission and weak red fluorescence emission (gates in Green autofluorescence and Red autofluorescence, respectively). d Inclusions
sorted sequentially by nuclear isolation, sucrose gradient, and flow cytometry are of high concentration and purity. Sorted inclusion samples viewed at
60x show high purity, with 80-90% of autofluorescent particles displaying autofluorescent properties consistent with FXTAS inclusions. 10-20% of
particles (orange arrows) display a high level of autofluorescence in the far-red wavelengths, indicating that a small degree of non-inclusion debris
may be present. Scale bars = 5 μm
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a resolution of 70,000 and a target of 1x106 ions or a
maximum injection time of 30 msec. MS/MS spectra
were acquired using a top 15 method where the top 15
ions in the MS spectra were subjected to high energy
collisional dissociation. MS/MS spectra were acquired
with a resolution of 17,500 and a target of 5x104 ions or
a maximum injection time of 50 msec. An isolation mass
window of 1.6 m/z was used for precursor ion selection,
charge states of 2-4 were accepted, and a normalized
collision energy of 27% was used for fragmentation. A
20-sec duration was used for dynamic exclusion. For
identification and quantitation of data-dependent acqui-
sition data, raw files were searched with Andromeda in
MaxQuant version 1.6.1.0 and further processed in Per-
seus version 1.6.0.2 or Scaffold version 4.8.4.
Additional details for all methods are provided in Add-
itional file 1: Methods.
Results
Intrinsic autofluorescence of human FXTAS inclusions
facilitates their isolation using preparative flow cytometry
During a series of immunofluorescence studies of FXTAS
inclusion-bearing frontal cortex, we observed that the in-
clusions emit broad-spectrum autofluorescence. Inclusion
autofluorescence has previously been reported in neuronal
intranuclear inclusion disease (NIID) [70, 110], but has
not been reported previously for FXTAS inclusions.
Examination of slides generated from multiple FXTAS pa-
tients revealed that the inclusions emit the lowest intensity
of autofluorescence at 360 nm and 620 nm, with maximal
brightness by visual inspection between 480 nm and 545
nm (Fig. 1 a). Stimulated emission depletion (STED) mi-
croscopy on a Leica SP8 STED 3x was used to measure
the excitation/emission spectra of FXTAS inclusions, and
the results corroborated what was seen on visual examin-
ation (Additional file 1: Figure S1a), with maximum emis-
sion intensity at 550 nm by STED. Autofluorescence has
been found in every FXTAS case examined thus far (~10
cases), with spectral properties quantitatively consistent
across samples. Additional experiments were performed
to ensure that inclusion autofluorescence is not an artifact
of fixation, mounting, or staining (unpublished data).
The constancy of FXTAS inclusion autofluorescence
has enabled us to isolate relatively pure samples of inclu-
sions using preparative flow cytometry. To minimize
contamination due to the known autofluorescence of
lipofuscin [27], we isolated nuclei from frozen postmor-
tem cortical tissue by a modification of previous
methods [58, 83, 94], followed by sucrose gradient frac-
tionation of disrupted nuclei to obtain a crude inclusion
fraction. Our approach, which substantially removes
cytoplasmic lipofuscin during the nuclear isolation,
largely eliminates non-inclusion autofluorescent cellular
material. Ultracentrifugation of nuclear homogenate on
a sucrose gradient produces a diffuse band of particles at
a density of ~1.30 g/ml, visible in FXTAS samples but
not in control samples (Additional file 1: Figure S1b).
Visualization of the particles within this band by fluores-
cence microscopy reveals autofluorescent particles that
exhibit the same spectral properties as in situ FXTAS in-
clusions. However, this inclusion-enriched isolate still
contains a substantial fraction of non-inclusion particles.
To obtain inclusion samples of greater purity, prepara-
tive FACS was used to sort inclusions based on their in-
trinsic autofluorescence (i.e., without the use of
antibodies). The population of particles in the 1.30 g/ml
banded material was sorted using size and autofluores-
cence characteristics (Fig. 1 b). Sorted populations of
particles viewed by microscopy exhibit the same spectral
properties as in situ FXTAS inclusions (Fig. 1 c). FACS-
sorted inclusions can be centrifuged and resuspended in
a smaller volume to obtain a concentrated sample of
relatively pure inclusions (Fig. 1 d). Although most of
the particles in these sorted samples exhibit the same
spectral properties as inclusions, some contaminants ap-
pear too bright at 620 nm to be considered as inclusions
and are likely lipofuscin particles that were not com-
pletely removed during the nuclear isolation process.
Taking these into account, we estimate that FACS sort-
ing inclusion preparations are of 80–90% purity.
FXTAS inclusions appear to be comprised mainly of
protein, with a smaller component of RNA, but do not
contain significant amounts of DNA
Inclusion-enriched sucrose fractions (1.30 g/ml density)
were used to provide a crude estimate of the general mo-
lecular composition of inclusions. The inclusions were
treated with either DNase I, RNase A/T1, Proteinase K, or
no enzyme; each sample was viewed by fluorescence mi-
croscopy utilizing autofluorescence (no immunostaining).
The no-enzyme and DNase I treatments exhibited wholly
intact inclusions, with no diminishment of autofluores-
cence intensity, inclusion size, or integrity, indicating that
DNA does not comprise a significant proportion of the
makeup of inclusions (Fig. 2). In comparison, RNase
treated inclusions displayed substantial loss of autofluores-
cence intensity, with many of the inclusions, while still
present, appearing to have lost structural integrity. This
observation suggests that RNA may play a significant role
in the structural makeup of the inclusions, which supports
previous evidence that FMR1 mRNA is present in inclu-
sions [135]. However, preliminary attempts to analyze the
RNA complement through RNAseq, although confirming
the presence of mRNA, were confounded by extensive
degradation of the RNA isolated from the inclusions. Fur-
ther efforts to determine the composition of the RNA spe-
cies within the inclusions are ongoing. Finally, Proteinase
K treatment alone completely abolished visualization of
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any inclusions, suggesting that the inclusions are predom-
inantly proteinaceous.
FXTAS inclusions are primarily heterogeneous protein
aggregates enriched for proteins involved in RNA binding
and protein turnover and degradation
MS-based proteomics was utilized to determine the pro-
tein composition of FXTAS inclusions purified from
frontal cortex of two FXTAS patients (cases B3 and B6
from Table S1) with high loads of inclusions (~9–14%
inclusion-bearing neuronal/astrocytic cells), as previ-
ously determined through immunohistochemistry. Pa-
tient samples were processed by nuclear isolation/
sucrose gradient centrifugation/preparative FACS to ob-
tain sorted inclusion samples. These samples were com-
pared by LC-MS/MS to total nuclear protein from the
same samples, as well as to the nuclear isolate from a
control non-FXTAS sample (case B8 from Table S1). In
general, there was no dominant protein among the in-
clusion-enriched proteins (see full MS dataset in Add-
itional file 1). Although histones comprised 25–70% of
each inclusion protein isolate, none of the histone spe-
cies was enriched in inclusions over total nuclear pro-
tein. The next highest abundance protein, ubiquitin,
only comprises ~5% of the inclusion protein comple-
ment. To identify proteins likely to be specifically in-
volved in inclusion formation, only those proteins whose
molar fractions equaled or exceeded 0.01% of the total
inclusion protein content for both sorted inclusion sam-
ples and showed at least 1.5-fold enrichment in both
sorted samples over their accompanying total nuclear
samples were considered for further analysis. One-hun-
dred seventy-six proteins fit these criteria out of a total
of ~1,900 proteins identified by MS analysis of the puri-
fied inclusions (Additional file 2). The enriched proteins
were scored and categorized by function according to
UniProt. Three major functional categories stood out
among the enriched proteins: RNA binding proteins,
proteins involved in protein turnover, and DNA binding
proteins (Fig. 3).
Over one-third of the inclusion-enriched proteins are
RNA binding proteins. Within this category, 17.3% are
ribonucleoproteins. Many of these ribonucleoprotein
species (mainly hnRNPs) are present at relatively high
abundance within the enriched fraction, half making up
over 0.2% in both inclusion samples, and two, hnRNPA1
and hnRNPA3, comprising 1-2% of both inclusion sam-
ples. A further 26.7% of the inclusion-enriched RNA
binding proteins are ribosomal proteins. However, al-
most all of these species were present at low abundance
(<0.1% of total inclusion protein). They also were not
found at higher levels in FXTAS total nuclear samples
compared with control total nuclear samples. We also
detected approximately forty proteins involved with
RNA splicing, the most abundant being U2AF (~0.2%)
and SFPQ (~0.5%); both are slightly enriched in the in-
clusion fraction (by 2.0- and 1.4-fold, respectively). How-
ever, there does not appear to be any overall trend for
enrichment, with the majority of detected splicing fac-
tors being slightly less abundant in the inclusions than
in the surrounding nuclear matrix.
A further 15% of inclusion-enriched proteins were
scored as involved in protein turnover; that is, proteins
that are tasked with binding and processing of other
proteins for recycling or removal. Although the protein
turnover category contains fewer members compared to
the RNA binding category, the protein species compris-
ing this category have the highest abundance levels in
inclusions. Within this category, 40% of members were
categorized as molecular chaperones, 22% play roles in
protein modification, and 22% were members of protea-
somal machinery.
Fig. 2 FXTAS inclusions are largely made up of protein and contain
a smaller component of RNA, but do not contain significant
amounts of DNA. DNase treatment did not affect the quantity,
integrity, or level of autofluorescence exhibited by isolated
inclusions, detected at 488nm, 555nm; not visualized at 647nm
without several fold increase in brightness. RNase treatment did not
affect the quantity of inclusions seen, but the autofluorescence
levels exhibited by inclusions was decreased. Postprocessing to
increase the brightness of RNase treated inclusions revealed that the
integrity of the inclusions appeared compromised. Protease
treatment completely abolished visualization of inclusions using
autofluorescence, and no inclusions were observed. Unless specified
(bright), all images were acquired for 208.1 ms
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Fig. 3 Categorization by function of inclusion-enriched proteins reveals large populations of proteins involved in RNA binding and protein
turnover. Proteins that were found present to at least 0.01% in both FXTAS sorted inclusion samples and showed at least 50% enrichment in
sorted inclusion samples over accompanying total nuclear samples were identified for categorization. A total of 176 proteins fit these criteria.
Proteins were scored by main function(s) as identified by UniProt, and each protein could have multiple scores. Percentages were calculated as
number of proteins with that score out of the total number of scores given in the dataset. The “Other” category contains proteins involved in
functions including biosynthetic processes, energy metabolism, immunity, and neural development, with no one single category exceeding 3%.
A total of 75 proteins were scored as RNA binding proteins and proteins participating in RNA metabolism (transcription, editing, splicing,
transport). Many of the higher abundance proteins in this category were hnRNPs. Although there were many ribosomal proteins found in this
dataset, almost all of them were found at low abundance (<0.1% of the total protein composition) and were not found to have more total
nuclear enrichment in FXTAS nuclei compared to control nuclei. We hypothesize that these proteins represent mainly background through the
isolation process and are present more as bystanders rather than main players in inclusion formation. A total of 32 proteins were scored as those
participating in protein turnover (protein folding, aggregation, modification, degradation). Within this category, the majority of protein species are
those involved in binding and processing proteins destined for recycling or removal. The protein species comprising this category have the
highest abundance levels in inclusions. A total of 21 proteins were scored as DNA binding proteins or proteins participating in DNA metabolism
(chromatin remodeling, replication, repair). Of these, 6 are players in DNA damage repair, including RAD50, RPA1, and XRCC6
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The final major functional category, DNA binding pro-
teins, makes up 10% of the population of inclusion-
enriched proteins, and 28.6% of these were categorized
as DDR mediators. Among these DDR mediators were
proteins such as RAD50, RPA1, and XRCC6.
For a more focused analysis of the highest-abundance
inclusion-enriched proteins, those proteins which make
up at least 0.5% of a sorted inclusion sample and which
were enriched by at least 50% were considered further.
Only 15 proteins fit these criteria (Table 1), with the
most prominent members being ubiquitin and SUMO 2.
Other proteins in this list include several hnRNPs and
chaperones. Only five proteins were enriched by at least
three-fold in both sorted inclusion samples: ubiquitin,
SUMO 2, myeloid leukemia factor 2 (MLF2), myelin
basic protein (MBP), and p62. Western blot to confirm
MS results for p62 was performed on five replicates of
control versus FXTAS brain nuclear lysates from control
(n=3) and FXTAS (n=4) patients. p62 was seen at 62
kDa and was approximately three-fold more intense in
FXTAS samples compared with control samples (Add-
itional file 1: Figure S2a), and immunofluorescence on
FXTAS brain smears confirmed the presence of p62 in
nuclear inclusions (Additional file 1: Figure S2b).
Fold change values for each of the FXTAS inclusion
samples over their accompanying FXTAS nuclear sam-
ples and the control nuclear sample are shown, with the
abundance values as a percentage of the total identified
protein molar composition for each sample displayed in
parentheses. Proteins identified were present in at least
one FXTAS sorted inclusion sample to at least 0.5% and
showed at least 50% enrichment in both FXTAS sorted
inclusion samples over corresponding FXTAS nuclear
samples. Only five of these proteins (bolded) were
enriched at least 3-fold in FXTAS inclusions over ac-
companying FXTAS total nuclear proteins, and only
SUMO 2/3, MLF2, and p62 were also found to be
enriched at least 3-fold in FXTAS total nuclear samples
over control total nuclear sample. Numeric values pre-
sented outside parentheses are fold change of inclusion
samples over nuclear samples. Values inside parentheses
show the abundance values as a percentage of the total
protein composition identified for inclusion samples
over nuclear samples.
SUMO 2/3 conjugates are present in FXTAS brain nuclei
at levels exceeding ten-fold over the levels found in brain
nuclei from controls
To confirm elevation of SUMO 2 in FXTAS brain nuclei,
western blot analysis was performed using a SUMO 2/3
antibody on protein lysates from whole brain tissue and
nuclear brain protein lysates from FXTAS (n=5) patients
and controls (n=3) (Fig. 4 a, Additional file 1: Figure S3).
Although MS analysis can distinguish SUMO 2 from
Table 1 Higher abundance proteins enriched at least 1.5x in FXTAS inclusions include protein modifiers, RNA binding proteins, and
chaperone proteins
FXTAS A Inclusions FXTAS B Inclusions








Small ubiquitin-related modifier 2 (SUMO2) 5.5 (0.60/0.11) 60.0 (0.60/0.01) 9.1 (4.37/0.48) 437.0 (4.37/0.01)
p62/ SQSTM1 8.0 (0.08/0.01) 40.0 (0.08/0.002) 30.0 (0.60/0.02) 300.0 (0.60/
0.002)
Myeloid leukemia factor 2 (MLF2) 9.3 (0.28/0.03) 93.3 (0.28/0.003) 27.3 (0.82/0.03) 273.3 (0.82/
0.003)
Ubiquitin (RS27A) 3.6 (0.65/0.18) 5.9 (0.65/0.11) 6.7 (5.17/0.77) 47.0 (5.17/0.11)
Myelin basic protein (MBP) 3.5 (0.46/0.13) 1.2 (0.46/0.38) 15.2 (0.76/0.05) 2.0 (0.76/0.38)
Heat shock protein HSP 90-alpha (HSP90AA1) 1.6 (0.08/0.05) 4.0 (0.08/0.02) 1.7 (0.67/0.39) 33.5 (0.67/0.02)
Heterogeneous nuclear ribonucleoprotein L (HNRNPL) 1.9 (0.13/0.07) 6.5 (0.13/0.02) 1.6 (0.52/0.32) 26.0 (0.52/0.02)
Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) 1.7 (1.12/0.65) 2.7 (1.12/0.41) 1.6 (2.16/1.32) 5.3 (2.16/0.41)
Heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) 1.8 (0.95/0.54) 2.6 (0.95/0.36) 1.6 (1.59/0.97) 4.4 (1.59/0.36)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) 1.9 (0.28/0.15) 1.3 (0.28/0.22) 2.0 (0.59/0.30) 2.7 (0.59/0.22)
Beta-actin (ACTB) 2.2 (0.75/0.34) 1.2 (0.75/0.61) 1.8 (1.33/0.75) 2.2 (1.33/0.61)
Alpha-crystallin B chain (CRYAB) 1.9 (1.29/0.68) 1.1 (1.29/1.22) 1.7 (2.66/1.53) 2.2 (2.66/1.22)
Tubulin alpha-1B chain (TBA1B) 1.6 (1.01/0.63) 1.0 (1.01/0.98) 1.6 (0.81/0.50) 0.8 (0.81/0.98)
Tubulin beta-2A chain (TBB2A) 1.7 (0.64/0.37) 0.9 (0.64/0.71) 1.5 (0.58/0.39) 0.8 (0.58/0.71)
Calcium/calmodulin-dependent protein kinase type II subunit alpha
(CAMK2A)
1.7 (0.43/0.25) 0.7 (0.43/0.61) 1.6 (0.59/0.38) 1.0 (0.59/0.61)
Only five of these proteins (bolded) were enriched at least 3-fold in FXTAS inclusions over accompanying FXTAS total nuclear proteins, and only SUMO 2/3, MLF2,
and p62 were also found to be enriched at least 3-fold in FXTAS total nuclear samples over control total nuclear sample
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SUMO 3, most antibodies recognize both species due to
their high level of sequence similarity. Each FXTAS nu-
clear sample exhibited an intense SUMO 2/3 smear ex-
tending from the well down to around 25–30 kb,
indicating an unusually large amount of conjugated
SUMO 2/3, especially at higher molecular weights. This
smear was not apparent in whole brain tissue lysates, indi-
cating that the SUMO conjugates are present primarily or
exclusively in the nuclear compartment, with the conju-
gates being diluted in whole tissue. Quantification re-
vealed an over ten-fold elevation of conjugated SUMO 2/3
in FXTAS nuclei compared to control nuclei. Interest-
ingly, no significant differences were seen between FXTAS
and control for the SUMO 1 isoform (Additional file 1:
Figure S4).
Immunofluorescence of control and FXTAS brain nu-
clei was used to localize the elevated SUMO 2/3. Staining
was performed in the far-red spectral region (620 nm)
where autofluorescence is minimal; secondary antibody-
only controls are shown for comparison. SUMO 2/3 stain-
ing produced an intensely bright signal within inclusions
(Fig. 4 b, top panels). All inclusions that were identified by
autofluorescence at 480 nm stained intensely positive for
SUMO 2/3 at 620 nm. In addition, bright SUMO 2/3 ag-
gregates found at 620 nm could be used to identify smaller
inclusion-like aggregates that were not immediately appar-
ent at 480 nm or 545 nm. This suggests that SUMO 2/3
accumulation may be an early and major participant in in-
clusion formation. Outside of the SUMO 2/3 aggregates,
there did not appear to be any generalized increase in
SUMO signal in the rest of the nucleus compared to con-
trol. The quantity of SUMO-staining aggregates became
apparent when looking at incompletely homogenized
clumps of cells in control versus FXTAS brain, where
SUMO staining only lightly and diffusely stained the cells
in control, whereas many SUMO 2/3 aggregates were
present in FXTAS (Fig. 4 b, bottom panels).
The same analysis of SUMO 2/3 immunofluorescence
was performed on 11-month-old, high premutation
CGG (hpCGG; ~170 CGG repeats), and wildtype (WT)
mouse brain tissue to determine whether SUMO 2/3 ag-
gregation also occurs in an FMR1 premutation mouse
model [10, 142]. Many SUMO 2/3 aggregates were ap-
parent in both male and female homozygous hpCGG
mouse brain but were not present in age-matched WT
mice (Fig. 4 c, Additional file 1: Figure S5a). However,
the number and size of the aggregates were smaller than
those present in human brain. Western blot analysis of
hpCGG mouse brain nuclear lysates did not exhibit the
same prominent SUMO 2/3 smears present in human
FXTAS brain, perhaps because the premutation mice
were still in the premutation phase (only 11 mo old)
whereas FXTAS patient postmortem brains were in the
later, neurodegenerative phase (>65 yr old) (Additional
file 1: Figure S5b). The same hpCGG slides were also ex-
amined for inclusion autofluorescence, which was not
detected. Finally, very few ubiquitin-staining inclusions
were found on the entire slide used to detect SUMO 2/3
immunofluorescence, consistent with the ~1.6% of cells
with inclusions in frontal cortex for these premutation
mice at 11 months of age [142], which was a much lower
percentage of inclusion-bearing cells compared to
SUMO 2/3 aggregate-bearing cells. This finding indi-
cates that SUMO 2/3 aggregation precedes the forma-
tion of canonical ubiquitin-staining FXTAS inclusions.
The levels of SUMO 2/3 in nuclei from FXTAS brains
exceed the levels found in several other common
neurodegenerative disorders
To determine whether the elevated SUMO 2/3 in
FXTAS is specific to this disorder or is representative of
a generalized neurodegenerative phenomenon, a variety
of other neurodegenerative brain samples were collected
for nuclear isolation followed by western blot (Fig. 4 d,
Additional file 1: Figure S6). No other disease consist-
ently exhibited elevated SUMO 2/3 immunoreactivity to
the same degree as FXTAS, but several other brain sam-
ples from patients exhibiting neurodegenerative disease
did exhibit higher than normal levels of SUMO 2/3, in-
cluding FTD, HD, and PSP. Although one patient diag-
nosed with AD did show an abnormally high SUMO 2/3
signal, this was not consistently recapitulated in other
AD samples. Brains from patients diagnosed with PD,
ALS, and FXS exhibited SUMO 2/3 levels similar to that
of control brains. These results are preliminary, as more
replicates were not possible due to insufficient sample
quantity, but they indicate that the consistently high
level of SUMO 2/3 seen in FXTAS samples is unique to
this disorder; although, SUMO 2/3 may play a role in
other inclusion and/or aggregate-bearing neurodegener-
ative diseases. Samples tested in the current study were
nuclear lysates, so diseases bearing cytoplasmic-only in-
clusions, such as PD and ALS, may have aggregates that
contain SUMO 2/3 in their cytoplasmic compartments
that would not be captured here. The role of SUMO 2/3
in other neurodegenerative disorders warrants further
study.
SUMO 2/3 immunoprecipitation proteomics reveal that
SUMO 2/3 is highly conjugated to proteins involved with
protein turnover, DNA damage/repair, and protection
against oxidative stress/damage in FXTAS
To further assess the targets of SUMO 2/3 conjuga-
tion in FXTAS patients, we performed IP with a
SUMO 2/3 antibody followed by LC-MS/MS to deter-
mine what population of proteins are modified by
SUMO 2/3 in FXTAS patients compared to controls.
IP methods were adapted from several sources [50,
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Fig. 4 (See legend on next page.)
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52, 145, 155]. In brief, nuclei were isolated from
frontal cortex tissue of two FXTAS cases and two
controls. Nuclei were lysed and heated in an SDS/Tri-
ton/deoxycholate buffer, then diluted to minimize de-
tergent interference for IP. Pulldown was performed
using a SUMO 2/3 mouse IgG antibody and anti-
mouse IgG magnetic beads. Western blot confirmed
that the pulldown successfully captured the SUMO 2/
3 smear (Additional file 1: Figure S7). LC-MS/MS of
the IP eluted proteins confirmed the high levels of
SUMO 2/3 pulldown in the FXTAS samples (Table
2). As with the MS analysis of the FXTAS inclusions,
no one protein dominated in the IP, indicating that
the elevated conjugated SUMO 2/3 present in FXTAS
is not due to its conjugation with one particular
protein.
(See figure on previous page.)
Fig. 4 a FXTAS nuclear protein samples exhibit over ten times higher SUMO 2/3 protein levels compared to control nuclear protein samples. FXTAS
nuclear protein samples exhibit a vibrant SUMO 2/3 smear indicating over 10 times higher levels of conjugated SUMO 2/3 over control nuclear protein
samples after normalizing to total protein levels (unpaired student’s t-test (single group) with p-value <0.005). Whole tissue sample signals were
extremely faint by comparison. No significant difference was seen between control and FXTAS samples for unconjugated SUMO 2/3. b SUMO 2/3
immunofluorescence reveals that SUMO 2/3 is present mainly as large, concentrated intranuclear aggregates in FXTAS brain cells, and FXTAS inclusions
always colocalize with SUMO 2/3 aggregation. SUMO 2/3 forms large, intranuclear aggregates in FXTAS brain cells that colocalize with FXTAS
inclusions. Immunofluorescence was performed using an Alexa 647 secondary antibody to minimize the effect of inclusion autofluorescence.
360nm+480nm images show inclusion autofluorescence. In FXTAS samples, SUMO 2/3 aggregates at 620nm are so vibrant that the signal intensity at
208.1ms is distorted, and the signal is bright even at an exposure of 10.1ms. No post-processing was done to alter brightness/contrast levels. Orange
arrows denote FXTAS inclusions. When looking at clusters of nuclei (bottom panels), control brain cells show diffuse SUMO 2/3 staining throughout
nuclei, but no aggregates, whereas FXTAS brain cells show large, circular aggregates in a large proportion of cells. c SUMO 2/3 aggregates are present
in mouse high premutation CGG brain nuclei but are not present in wildtype brain nuclei. Intranuclear SUMO 2/3 aggregates are also seen in 11-
month-old premutation CGG male mouse brain, but not in age-matched male wildtype mice. Aggregates were smaller and fewer than those seen in
human FXTAS brain. Immunofluorescence was performed using an Alexa-647 secondary antibody. No postprocessing was done to alter brightness/
contrast levels. Orange arrows denote SUMO 2/3 aggregates. d The SUMO 2/3 smears found in FXTAS nuclear protein samples are not present to the
same degree in other neurodegenerative brain samples investigated. Western blot analysis was performed on nuclear lysates from human frontal
cortex tissue obtained from a variety of neurodegenerative disorders. Due to the lack of availability of sufficient material, replicates were not possible
for several samples. Where replicates were possible, error bars are shown. Scale bars = 10 μm
Table 2 Among higher abundance proteins that were mildly enriched in FXTAS samples were other protein turnover agents and
proteins involved in non-homologous end joining (NHEJ)
Proteins Averaged FXTAS over Control
p62/SQSTM1 237.5 (0.19/0.0008)
Small ubiquitin-related modifier 2 (SUMO2) 11.4 (9.88/0.87)
Small ubiquitin-related modifier 3 (SUMO3) 12.9 (0.09/0.007)
Small ubiquitin-related modifier 1 (SUMO1) 7.2 (0.43/0.06)
Ubiquitin (RS27A) 3.9 (0.51/0.13)
Carbonyl reductase [NADPH] 1 (CBR1) 20.5 (0.41/0.02)
14-3-3 protein theta (1433T) 15.0 (0.12/0.008)
Gelsolin (GSN) 11.0 (0.11/0.01)
Peptidyl-prolyl cis-trans isomerase A (PPIA) 5.4 (0.54/0.10)
Triosephosphate isomerase (TPIS) 3.5 (0.07/0.02)
X-ray repair cross-complementing protein 5 (XRCC5) 3.3 (0.20/0.06)
Creatine kinase B-type (KCRB) 3.2 (0.51/0.16)
Poly [ADP-ribose] polymerase 1 (PARP1) 2.7 (0.38/0.14)
Splicing factor U2AF 35 kDa subunit-like protein (U2AF5) 2.6 (0.13/0.05)
Isocitrate dehydrogenase [NADP] (IDHP) 2.3 (0.09/0.04)
X-ray repair cross-complementing protein 6 (XRCC6) 2.0 (0.34/0.17)
Centromere protein V (CENPV) 1.7 (0.38/0.22)
ATP-dependent RNA helicase (DDX1) 1.4 (0.10/0.07)
Profilin-1 (PROF1) 1.3 (0.08/0.06)
Alpha-crystallin B chain (CRYAB) 1.3 (2.11/1.63)
Excluding SUMO 2, proteins that showed at least 3-fold enrichment in both FXTAS samples over age matched control samples are bolded
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Fold change values for the averaged FXTAS IP sam-
ples over the averaged age-matched control IP samples
are shown. Proteins that were present in at least one
FXTAS sample to at least 0.1% and showed at least 20%
enrichment in both FXTAS samples over age matched
control samples are displayed here. The high level of en-
richment in SUMO 2 signal present in FXTAS samples
confirms the success of the IP. Excluding SUMO 2, pro-
teins that showed at least 3-fold enrichment in both
FXTAS samples over age matched control samples are
bolded. Numeric values presented outside parentheses
are fold change of averaged FXTAS samples over aver-
aged control samples. Values inside parentheses show
the averaged abundance values as a percentage of the
total protein composition identified for FXTAS samples
over control samples.
Among the more abundant SUMO 2/3 targets identi-
fied by IP were proteins with chaperone/protein-folding
functions, including αβ-crystallin (CRYAB) and peptidyl-
prolyl cis-trans isomerase A (PPIA) [13, 48]; conjugating
proteins known to be involved in protein turnover, in-
cluding ubiquitin, SUMO 1, and SUMO 2/3 [79, 96,
102]; and prominently, the ubiquitin-binding shuttling
protein p62 [26, 107, 143]. We also detected proteins
known to be involved in non-homologous end joining
(NHEJ), including poly [ADP-ribose] polymerase 1
(PARP1), X-ray repair cross-complementing protein 6
(XRCC6/Ku70), and X-ray repair cross-complementing
protein 5 (XRCC5/Ku80) [22, 146]. Several proteins in-
volved in cellular protection against oxidative stress,
such as carbonyl reductase 1 (CBR1) [67, 121, 151] and
mitochondrial isocitrate dehydrogenase (IDH2) [47, 61,
69], were also identified. Other than SUMO 2, only 4
proteins were enriched at least 3-fold in FXTAS IPs over
control IPs: SUMO 1, SUMO 3, Ubiquitin, and p62.
FMRpolyG is a minor component in FXTAS inclusions and
IP conjugates
It has been posited that FXTAS inclusions are largely
made up of aggregates of FMRpolyG and interacting
proteins [19, 125, 137]. However, endogenous FMRpo-
lyG has never been identified in FXTAS patient samples
through direct protein sequencing. Importantly, we have
identified FMRpolyG in both sorted inclusion samples
and FXTAS SUMO IP samples (Table 3). However,
FMRpolyG constituted an extremely minor component,
at 0.003% of the total protein molar complement in one
inclusion sample and 0.04% in the other sample (~30–
400 ppm molar abundance). Importantly, neither of the
FXTAS nuclear lysate samples nor control brain con-
tained detectable levels of FMRpolyG. Thus, FMRpolyG
can only be detected with significant enrichment. Add-
itionally, two proteins, LAP2β and TRA2A, which have
been proposed to co-aggregate with FMRpolyG within
inclusions [19, 125], were also found at very low levels.
LAP2β was detected at 0.02% and 0.04% in inclusions
while TRA2A was detected at 0.0001% in the inclusion
samples. As a positive control for detection of FMRpo-
lyG, we expressed an FMRpolyG GFP fusion construct
in SK-N-MC neuroblastoma cells (Fig. 5 a). We identi-
fied three proteotypic peptides mapping to FMRpolyG-
GFP that were not detected in null or GFP transfected
cells (Fig. 5 b). Finally, FMRpolyG was also detected in
both FXTAS IP samples, but was again at a low abun-
dance (0.01%) and detected through just one hit of one
tryptic peptide in each sample (Table 3).
FXTAS inclusions do not co-localize with the FMR1 gene
The observation that FXTAS inclusions are exclusively
solitary and intranuclear has led to the hypothesis that in-
clusion formation may occur at the active FMR1 locus,
perhaps forming due to the accumulation of DDR proteins
around the damage-prone expanded repeat [32, 42, 43].
To test this, a DNA fluorescence in situ hybridization
(FISH) composite probe set, comprised of 119 individual
DNA oligonucleotides, was generated to target the human
FMR1 locus. The FISH probe was generated using a modi-
fied PCR protocol to avoid the repeat-rich regions sur-
rounding and including the FMR1 locus. Probe specificity
and efficiency was tested on a variety of human cells, in-
cluding metaphase and interphase fibroblasts cultured
from skin biopsies, lymphocytes, and brain smears made
from fresh frozen human frontal cortex tissue (Fig. 6 a). In
fibroblasts, over one thousand nuclei from both female
and male samples were scored for probe binding, and 97%
of nuclei contained clear and specific FISH probe signal.
In human brain nuclear smears, over 500 nuclei from one
FXTAS patient were scored for FISH probe binding, inclu-
sion presence, and localization of the FMR1 locus relative
to inclusions. 92% of the scored nuclei contained clear
and specific probe signal, and 8.7% of the scored nuclei
contained nuclear inclusions (Fig. 6 b). Previous reports of
inclusion load in FXTAS frontal cortical tissue range from
2–20% of neurons and astrocytes [38], and our quantifica-
tion of inclusion load based on autofluorescence falls
within this range. Of the inclusion- and probe-bearing nu-
clei, 95.2% of them clearly showed no-colocalization be-
tween the inclusion and the FMR1 locus, and the
remaining 4.8% showed possible co-localization (Fig. 6 b).
These data do not support the hypothesis that the FMR1
locus consistently co-localizes with FXTAS inclusions.
Discussion
A principal outcome of the current study is that the pro-
tein complement of the FXTAS intranuclear inclusions
is not dominated by a single, enriched protein. Rather,
the inclusions comprise a large number of proteins, each
present at only a few percent or less of the total proteins
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identified. The current observations both validate and
expand upon an earlier, more limited study of FXTAS
inclusions [58]; with a number of proteins identified pre-
viously now quantified (see: Additional file 1) as well as
many additional protein components identified (e.g.
SUMO 2/3, p62). Moreover, the current study has
followed up the finding of SUMO2/3 enrichment by
using immunoprecipitation to identify proteins to which
these modifiers are ligated.
The strong enrichment for proteins involved in protein
turnover as well as the overall heterogeneous population
indicates that the inclusions are principally repositories
of proteins destined for removal. There are several possi-
bilities for why these proteins are aggregating. There is
good evidence for the presence of RNA in the inclusions,
and particularly FMR1 mRNA [135], which may serve as
driver for aggregation. In support of the involvement of
RNA, RNase treatment does affect the integrity of the
inclusions (Fig. 2), and 36% of inclusion proteins are
RNA binding proteins, which further supports the pres-
ence of RNA (Fig. 4). Although RNA sequencing of
FXTAS inclusions would be an excellent way to ascer-
tain what RNA species might be playing roles in inclu-
sion formation, efforts to characterize the RNA within
the inclusions have not been successful thus far due to
extensive degradation of the RNA isolates. This could be
due to either the strategy used in this study to isolate in-
clusions or due to intrinsically degraded RNAs within
the inclusions.
In addition, SUMO 2 may play a role in aggregation.
SUMO proteins have been well-studied in the context of
neurodegenerative disease for the diverse roles that they
can play as protein modifiers [4]. Although SUMO 2
was found to co-aggregate with polyQ-ATXN7, and
mouse models showed accumulation of SUMO 2 in
SCA7 patient brain [90], SUMO 2 had not previously
been reported as a major inclusion protein. The intensity
of the SUMO 2 signal in FXTAS compared to other
neurodegenerative diseases suggests something specific
in FXTAS which is not present or not as apparent in
other inclusion disorders. Unlike the current study, al-
most all studies reporting a role for SUMO in other neu-
rodegenerative diseases have found roles for SUMO 1
rather than SUMO 2/3 [29, 85, 132, 152]. SUMO 1 is
the dominant SUMO species and the majority of target
proteins are exclusively modified by SUMO 1 [149].
However, in response to cellular stress, including heat
shock, oxidative stress, and DNA damage, SUMO 2/3
forms polySUMO chains, while SUMO 1 may only cap
these chains [4, 140]. A study in HD found higher levels
of high molecular weight SUMO 2/3 in insoluble frac-
tions of HD affected striatum and suggested that this re-
sulted from toxic mutant huntingtin protein inducing a
cellular stress response [105]. Increased oxidative stress
and DNA damage in FXTAS have been well reported [2,
117, 120, 131]. PolySUMOylation has been found to
drive formation of biomolecular condensates through
multivalent interactions [116], so it is plausible that the
polySUMO chains found in FXTAS inclusions may be a
driver of, or participate in the formation of inclusions.
Since SUMO 2 aggregation appears to precede forma-
tion of canonical ubiquitin-containing inclusions, it is
possible that SUMO 2 aggregation helps initiate inclu-
sion formation.
Beyond polySUMOylation, other inclusion-enriched
proteins point to a global increase in DNA damage.
SUMO 2 and ubiquitin are both found at high levels in
FXTAS inclusions modifying a large pool of proteins,
and SUMO 2 IP was able to pull down large amounts of
ubiquitin in FXTAS samples. Therefore, it is likely that
mixed ubiquitin/SUMO chains are present. There have
been reports that ubiquitin and SUMO 2 compete for
the same modification sites on proteins, and may have
opposing effects [75, 139], but SUMO 2/3 is also known
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to form mixed chains with ubiquitin that can act co-
operatively to recruit DDR mediators to damaged sites
or enhance protein degradation [4, 41]. Moreover, in-
creased modification of proteins by SUMO-2/3 is a cyto-
protective response against cell stress [86], which is
clearly involved with FXTAS pathogenesis. p62 is also a
known player in DDR response, and is known to be a
cargo receptor that directs tagged proteins destined for
degradation by the autophagosome and has previously
been considered a major component of cytoplasmic in-
clusions [80, 154]. We speculate that its binding dynam-
ics are not significantly different in the nucleus.
Monomeric p62 is able to bind ubiquitinated substrates
through its ubiquitin-associated domain [56], and it has
Fig. 5 a Vector pBR-CMV-5ATG-63-EGFP produces FMRpolyG containing 63 CGG repeats fused to EGFP under a strong CMV enhancer and
promoter. As a positive control for FMRpolyG detection by LC-MS/MS, an expression plasmid was generated with a CMV promoter driven
FMRpolyG-GFP fusion construct. The human FMR1 5′ untranslated region (UTR) and Exon 1 sequence, from Transcriptional Start Site I (TSS-I) to
the first three base pairs of Exon 2, were placed upstream and in frame with EGFP to create a stable fusion protein. The translational start site of
FMRpolyG was modified from the native ACG to the canonical ATG to further drive FMRpolyG expression. b LC-MS/MS analysis of FMRpolyG-GFP
expressed in an SK-N-MC heterologous cell expression system identifies multiple proteotypic peptides. Transiently transfected SK-N-MC cells
containing the pBR-CMV-5ATG-63-EGFP plasmid were SDS solubilized and whole cell protein lysates were trypsin digested and analyzed by LC-
MS/MS. GFP signal was observed in FMRpolyG and GFP expressing cells, but not null transfection controls, indicating successful transfection of
the constructs. Peptide sequence coverage of FMRpolyG-GFP (48%) is indicated in yellow with modified residues in green. LC-MS/MS identified
three unique FMRpolyG-GFP peptides present only in FMRpolyG-GFP expressing cells that map to native FMRpolyG protein. A representative
mass spectrum of the FMRpolyG specific peptide SPPLGGGLPALAGLK is provided with y/b ions labeled
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Fig. 6 (See legend on next page.)
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been shown to actively participate in DNA damage re-
pair, acting as a shuttle to transport modified proteins to
the UPS or the autophagosome for removal [51, 143]. In
addition, p62 regulation has been directly linked to cal-
pain protease activity [20, 156], which may provide a link
between the results presented here and Ca and calpain
dysregulation seen previously in FXTAS [117].
Recently, we demonstrated that μ-calpain activity was
chronically elevated in cortical and hippocampal tissues
prepared from mice expressing FMR1 CGG expansions
repeats in the high range (premutation mice), beginning
as early as age 6 weeks and reaching >2-fold that of age
matched WT mice by 6 months [117]. The increased μ-
calpain activity is the likely consequence of chronically
elevated cytoplasmic Ca2+ and oxidative stress within
premutation neurons [117]. Elevated μ-calpain activity in
premutation brain was also associated with a 2-fold
higher p25/p35 ratio, dysregulation of Cdk5, and ele-
vated P-Ser1981-ATM – all by 6 months. These findings
were in accord with corresponding molecular outcome
measures in premutation hippocampal neurons at 7
DIV, the latter outcomes all normalized by the ER-Ca2+
channel inhibitor dantrolene [117]. Neuronal μ-calpain
activity has been implicated as a primary mechanism
regulating p62, which acts as an autophagic receptor that
recognizes misfolded protein aggregates targeted for
lysosomal degradation [12, 33, 95]. Adaptive autophagy
in response to conditions of oxidative stress can have
protective or pathological influences on neurons. Basal
autophagy is important for the turnover of organelles
and proteins preventing accumulation neurotoxic aggre-
gates associated with neurodegeneration [71]. However,
autophagy is vulnerable to other stress signals that can
disrupt adaptive functions, with abnormal Ca2+/calpain
regulation providing a mechanistic link between autoph-
agy and apoptosis [103, 150], suggesting that chronically
elevated Ca2+ and calpain activation may drive an au-
tophagic survival response into maladaptive autophagy
that contributes to neuronal death in FXTAS. Consider-
ing the significantly elevated levels of p62 and SUMO2
in the nuclear compartment and inclusions of FXTAS
brains, we posit involvement of maladaptive autophagy
in the neurodegenerative phase of FXTAS. This may not
be overly speculative as ATM-mediated DNA repair is a
consequence of p62 accumulation and has been linked
to neurodegeneration [63, 81, 141].
Based on the current data, we propose a model for in-
clusion formation (Fig. 7) wherein a cellular stress re-
sponse from a global increase in ROS and mitochondrial
dysfunction [100, 117, 120], perhaps exacerbated by
ROS-induced DNA damage, results in increased load of
damaged/oxidized proteins as well as proteins that are
involved with DDR. Ubiquitin and SUMO 2/3 target
these proteins for degradation. However, if the produc-
tion of these damaged and/or tagged proteins exceeds
the capacity of the proteasomal machinery within the
nucleus, the proteins alone or in combination with vari-
ous mRNA species (e.g., FMR1 CGG repeat mRNA)
known to be present in the inclusions [135] may drive
aggregation. Macroscopic aggregation would appear as
an inclusion, which would not be possible for the UPS
to degrade, and may even impair proteasomal function
[80]. Autophagy is the normal cellular mechanism for
aggregate degradation, and p62 binds the aggregation to
ferry it to the autophagosome for removal [143], but be-
yond a certain point, the inclusion becomes too large to
exit the nucleus, resulting in a chronic nuclear accumu-
lation. The UPS system has been shown to exhibit de-
creased function with aging, and there has been some
evidence of UPS impairment in other neurodegenerative
diseases, which may explain why FXTAS symptoms and
inclusion formation are most apparent at a later age [9,
66, 84, 99]. In addition, inhibition of the UPS system has
been shown to generate inclusion-like structures, which
further supports the connection between inclusion for-
mation and UPS impairment [76, 77, 110].
One interesting result of the current study was the find-
ing of extremely low levels of FMRpolyG either within in-
clusions or in FXTAS nuclei. It has been proposed that
FMRpolyG, in combination with proteins such as LAP2β
and TRA2A, aggregate to form FXTAS inclusions [15, 19,
118, 125, 137]. Our study is the first to identify
(See figure on previous page.)
Fig. 6 a DNA FISH probe generated for the FMR1 locus successfully tags the DNA locus in fibroblasts, lymphocytes, and brain nuclei. DNA FISH
probe generated using PCR amplification to tag the FMR1 locus cleanly tags the FMR1 locus at high efficiency in all cell types examined.
Metaphase plates generated using control patient-derived fibroblasts exhibit expected tagging patterns, with male samples exhibiting one tag
located towards the end of the long arm of the X chromosome, and with female samples exhibiting two such tags. Scoring of over 1100
fibroblast cells in a grid-like fashion showed 97% of cells exhibited sensitive and specific binding. Patient-derived lymphocytes exhibited similar
binding and efficiency. Brain nuclei exhibited slightly lowered binding efficiency at 92%, possibly due to degradation of cells due to pre and
postmortem conditions. b The FMR1 locus does not preferentially co-localize with inclusions. Out of 563 FXTAS nuclei scored, 518 of the nuclei
displayed sensitive and specific probe binding, representing an approximate FISH probe efficiency of 92% in brain tissue. Forty-five nuclei had
either no probe signal or multiple probe signals. Forty-nine of the nuclei scored positive for inclusions, representing about 8.7% of the total
nuclei present. Forty-two of inclusion-bearing nuclei also showed sensitive and specific probe binding. Forty of these nuclei showed negative
colocalization between the FMR1 probe and inclusion, while 2 nuclei showed possible colocalization between the FMR1 probe and the inclusion.
These data indicate that the FMR1 gene does not co-localize with FXTAS inclusions
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endogenous FMRpolyG in FXTAS patient samples by dir-
ect protein sequencing. However, although the current
study did detect minute quantities of FMRpolyG in inclu-
sions and in SUMO 2/3 IP-enriched samples, the levels
render it unlikely that FMRpolyG is a main driver or ma-
terial participant in the formation of FXTAS inclusions.
Moreover, FMRpolyG was undetectable in total nuclear
samples, indicating that it exists at extremely low en-
dogenous levels. Although LAP2β and TRA2A were also
detected in inclusions, they were also found at very low
levels (Additional file 1). LAP2 β is estimated to be present
at about the 0.02-0.04% level, whereas TRA2A is present
only at ~0.0002% (2 ppm) and is actually about 10- to 15-
fold lower in the inclusions than in the surrounding nu-
clear milieu. Therefore, although LAP2β AND TRA2A
have been observed by others to co-localize with FMRpo-
lyG in FXTAS inclusions [19, 125], it is unlikely that these
proteins substantively contribute to inclusion formation.
Part of the difficulty in assessing the involvement of
potential inclusion proteins such as FMRpolyG, LAP2 β,
and TRA2A by immunocytochemistry is that the
method, though great for localization of proteins, is not
a sound method for quantification, since antibody stain-
ing efficiency and methodology can have large effects on
the intensity of staining. LAP2β and TRA2A are cases in
point, as previously published immunofluorescence stud-
ies have demonstrated the presence of these proteins in
inclusions, yet the actual levels of these proteins in in-
clusions are extremely low. As another example, we per-
formed immunofluorescence on FXTAS inclusions using
previously published antibodies against FMRpolyG [15],
and we found highly variable staining patterns in inclu-
sions, varying from very faint, circumscribed, and very
bright, all on the same slide (Additional file 1: Figure
S8a). Thus, although the RAN translation pathogenic
model cannot be ruled out by the current results, the
current findings underscore the need for more studies
that involve endogenous expression rather than in vitro,
Fig. 7 Diagrammatic representation of hypothesized FXTAS
inclusion formation. Within FXTAS brain nuclei, proteins (yellow
hexagons) destined for removal are tagged with ubiquitin and
SUMO 2/3 chains, which are bound by the UPS for degradation.
Polyubiquitinated and polySUMOylated proteins may form small
aggregates with each other and/or RNA, at which point p62 will
shuttle the aggregate out of the nucleus to an autophagosome for
removal. Over time, as the FXTAS patient experiences higher levels
of oxidative stress and DNA damage and decreased functioning of
the UPS due to aging or injury, the levels of damaged/oxidized
proteins and DNA damage mediators requiring removal increase.
Paired with decreased UPS functionality, these proteins get tagged
for removal but build up in the nucleus, aggregating with other
proteins and RNA. p62 may attempt to shuttle the aggregate out to
the autophagosome, but if the accumulation becomes too large,
p62 has no way of shuttling the mass out of the nucleus in post-
mitotic cells, resulting in an inclusion
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induced, or high-expression models. Finally, the current
study also shows that co-localization between the FMR1
gene and FXTAS inclusions does not consistently occur,
which rules out DDR as a response to damage at the
FMR1 locus as the initiator of inclusion formation.
The current study used a novel method to purify en-
dogenous FXTAS inclusions from human brain whereby
the intrinsic autofluorescence of the inclusions was used
as a means for their separation, via preparative FACS,
from other nuclear particles and organelles (e.g., nucleoli).
The vast majority of studies of the protein composition of
inclusions and other nuclear or cytoplasmic aggregates in
neurodegenerative disorders, including our own [6, 58],
have relied on immunocytochemistry and other staining
methods [1, 3, 31, 65, 73, 98, 110]. Such methods depend
not only on the uniform presence and accessibility of the
specific proteins being probed, but also on the properties
of antibody sensitivity and specificity. Moreover, many
studies have utilized in vitro induction of inclusion-like
bodies, which may not fully recapitulate endogenous con-
ditions [77, 91, 97, 133, 153, 157]. Among the few studies
that have purified endogenous inclusions from human pa-
tients for proteomics, methods for purification have relied
on immunolabeling or sequential extraction by detergents
or chaotropes for which it was assumed that the most in-
soluble fraction was purified inclusion [37, 62, 93, 101,
112, 128, 144]. These methods introduce bias if antibodies
were used, and insoluble fractions may or may not contain
a truly pure population of inclusions. The method used in
this study avoids these areas of bias by utilizing autofluor-
escent properties of FXTAS inclusions for FACS. As a
concrete example of this distinction, the autofluorescent
inclusions are quite distinct from the other major intra-
nuclear organelle, the nucleolus, which is completely non-
autofluorescent (Additional file 1: Figure S8b).
The discovery of autofluorescence in FXTAS inclu-
sions allows us to more specifically identify and isolate
inclusions, but also calls for more stringent guidelines
when examining inclusions by immunofluorescence.
This finding does not necessarily nullify past immuno-
fluorescence results on inclusions, but such results
should now be reassessed using immunofluorescence
strategies that take autofluorescence into account. Such
strategies are already in use in the field of NIID, which
noted autofluorescent inclusions at certain wavelengths
[70, 110]. More detailed recommendations will be pub-
lished in a separate technical paper. However, in brief,
FXTAS inclusion autofluorescence interferes most
strongly in the green, yellow, and orange spectrum.
Since the blue range of the spectrum is usually reserved
for DAPI staining, efforts should be made whenever pos-
sible to perform inclusion immunofluorescence in the
far-red spectrum. There are still low levels of autofluo-
rescence in that spectral region. Therefore, slides with
secondary-only antibody staining should be imaged
using the same settings as those with primary antibody
staining of inclusions and provided for comparison. If it
is necessary to perform immunofluorescence at a wave-
length where autofluorescence is substantial, the anti-
body used must first be verified to have sufficient
sensitivity and specificity to overcome autofluorescence.
The use of an autofluorescence-based method of puri-
fying inclusions is novel; therefore, it is important to ver-
ify that what is collected from FACS is a substantially
pure population of inclusions. In the current instance,
microscopy of the sorted inclusions verified that their
autofluorescence profile was the same as that of inclu-
sions in situ (Fig. 1 c). Moreover, western blot and im-
munofluorescence analyses verified that two of the
newly-identified inclusion proteins that were most
enriched by MS are increased both in FXTAS nuclei and
in FXTAS inclusions (Fig. 6, Additional file 1: Figure
S7). Interestingly, several of the proteins found to be
enriched in FXTAS inclusions correspond to proteins
found in the inclusions of other neurodegenerative dis-
orders. Two of the FXTAS inclusion proteins with great-
est enrichment – ubiquitin and p62 – have previously
been well-documented. Ubiquitin is a component in
some forms of FTD, HD, some forms of spinocerebellar
ataxia (SCA), PD, ALS, dentatorubral-pallidoluysian at-
rophy (DRPLA), and NIID [11, 28, 49, 70, 72, 87, 123].
p62 has also been found in other inclusion disorders, in-
cluding FTD, PD, and AD [49, 88, 154]. A third protein
enriched in FXTAS inclusions, MLF2, has previously
been found to co-aggregate with p62 and poly (gly-ala)
in mice, and it alleviated poly-Q associated toxicity in
Drosophila and rat models [36, 124]. The presence of
MBP enrichment in FXTAS inclusions is not well under-
stood, as MBP is traditionally known to be a cytoplasmic
oligodendrocyte protein associated with myelination.
However, variant forms of it have been found to inhabit
oligodendrocyte nuclei [108] and to play unrelated func-
tional roles in astrocytic and neuronal nuclei [74]. Re-
gardless, it has previously been observed as a FXTAS
inclusion protein [58] and further investigation into its
role is warranted. In addition, the functional families of
proteins found enriched in inclusions are similar to what
has been seen in other types of inclusions. RNA binding
proteins, and especially hnRNPs, have previously been
detected in other types of inclusion disorders, as well as
chaperones, particularly heat shock proteins [21, 24, 34,
65, 92, 111]. The presence of proteasomal proteins in
FXTAS inclusions is not surprising as a connection be-
tween the UPS and inclusions has long been suspected.
Aside from comparison to inclusion composition in
other disorders, the FXTAS inclusion composition was
also compared to that of lipofuscin to rule out the possi-
bility that lipofuscin was a significant component of
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sorted FXTAS inclusions. Lipofuscins are intracytoplas-
mic, perinuclear pigment granules that are composed of
the residue of lysosomal degradation of aggregated/dam-
aged proteins. It accumulates in normal aging human
brain, and autofluoresces throughout a broad range of
wavelengths. The main difference in inclusion and lipo-
fuscin autofluorescence is in the far-red wavelengths,
where lipofuscin autofluorescence is significantly more
intense than inclusion autofluorescence (Additional file
1: Figure S1). It is unlikely that sorted inclusions contain
a significant component of lipofuscin for the following
reasons: (i) the nuclear isolation step should have largely
eliminated extranuclear cell debris, which would include
the cytoplasmic lipofuscin; (ii) the FACS sorted fraction
from the nuclear isolates was only present in the FXTAS
cases, not in controls, whereas lipofuscin is present in
controls as well as FXTAS cases; (iii) the sorted inclu-
sions were additionally viewed by microscopy to ensure
that a minimal proportion of sorted particles were
brightly fluorescent in the far-red wavelength (Fig. 1d);
and (iv) we compared lipofuscin protein components as
identified by MS in a previous publication to the com-
position of the FXTAS inclusions determined in the
current study [106]. Out of 49 identified major lipofuscin
proteins, 7 were not found in our dataset, 7 were found at
extremely low levels (<0.005%), and almost all the proteins
that were found in both datasets were not enriched in
FXTAS inclusions over total nuclear samples.
The current investigation has some limitations that bear
consideration. First, although the purification process for
inclusions is robust and more specific than other inclusion
isolation processes in the field, we estimate that as much as
10–20% of noninclusion material may remain in the final
preparations. This could allow some proteins that are not
within the inclusion to be detected by MS, although the
comparison to accompanying nuclear samples – establish-
ing levels of enrichment – should help to mitigate this
problem. Second, due to the need for long sorting times
and amounts of brain tissue required to isolate sufficient
numbers of inclusions for MS, only two FXTAS patients
were analyzed. Third, a limitation of the MS analysis is that
the quantification and percentages of proteins composing a
population is limited by the population of proteins detected.
Therefore, if there are undetectable proteins due to insuffi-
cient solubility, lack of available tryptic cut sites, or unfore-
seen pos-translational modifications, these would not be
represented in the protein population. Regarding FMRpo-
lyG, it has been reported that solubilization may be challen-
ging. However, we used mild heating in a strong detergent
buffer, the same strength as that used in a previous western
blot of FMRpolyG [137], as well as formic acid; we did not
observe any precipitate formation. Previously, only two
western blots for FMRpolyG on native human brain tissue
have been published [125, 137], and both utilized thermal
denaturation by boiling the tissue samples. It may be that
solubilization problems arise due to heat-dependent de-
naturation/aggregation, as has been established previously
[8, 40, 122, 138, 148].
Conclusions
We have performed a detailed analysis of the protein
composition of isolated FXTAS inclusions using their
distinct autofluorescent properties as a means for pre-
parative FACS-based purification. Although the current
study has helped to refine our understanding of the role
played by inclusions in FXTAS pathogenesis, further in-
vestigation into the role of SUMO2/3 in FXTAS patho-
genesis is warranted, as well as a re-investigation of the
roles of FMRpolyG in this disorder. Finally, we wish to
point out that models proposed for mRNA sequestration
remain viable [60, 115, 126, 127, 130], and these models/
mechanisms should be investigated further.
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